1. Home
  2. XOMA vs LXRX Comparison

XOMA vs LXRX Comparison

Compare XOMA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XOMA Corporation

XOMA

XOMA Corporation

HOLD

Current Price

$42.15

Market Cap

746.0M

Sector

Health Care

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$2.55

Market Cap

703.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XOMA
LXRX
Founded
1981
1995
Country
United States
United States
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.0M
703.3M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
XOMA
LXRX
Price
$42.15
$2.55
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$52.50
$4.15
AVG Volume (30 Days)
106.4K
2.3M
Earning Date
05-08-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.78
EPS
N/A
N/A
Revenue
N/A
$49,803,000.00
Revenue This Year
$24.59
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.64
N/A
Revenue Growth
N/A
60.24
52 Week Low
$22.29
$0.80
52 Week High
$42.81
$2.53

Technical Indicators

Market Signals
Indicator
XOMA
LXRX
Relative Strength Index (RSI) 61.87 74.41
Support Level $37.00 $1.11
Resistance Level $42.25 $2.53
Average True Range (ATR) 0.41 0.13
MACD -0.08 0.05
Stochastic Oscillator 84.15 97.10

Price Performance

Historical Comparison
XOMA
LXRX

About XOMA XOMA Corporation

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: